

SUPPLEMENTARY TABLE 1. Absolute and relative differences in percentage of COVID-19 patients aged ≥20 years treated with monoclonal antibodies, Lagevrio, and Veklury* by race and ethnicity† — PCORnet, the National Patient-Centered Clinical Research Network sites, 30 U.S. sites, April–July 2022

Medication type/ Race and ethnicity	No. of COVID-19 patients [§]	No. (%) treated	P-value [¶]	Absolute difference in % treated**	Relative difference in % treated**
Monoclonal antibodies					
Total	260,055	11,606 (4.5)	NC	NC	NC
Race					
AIAN/NHOPI	2,145	68 (3.2)	<0.001	-1.8	-36.2
Asian	12,062	341 (2.8)	<0.001	-2.1	-43.1
Black	30,482	1,162 (3.8)	<0.001	-1.2	-23.3
White	187,369	9,313 (5.0)	NC	Ref	Ref
Multiple or other	12,396	437 (3.5)	<0.001	-1.4	-29.1
Ethnicity					
Hispanic	23,711	565 (2.4)	<0.001	-2.5	-51.3
non-Hispanic	217,739	10,649 (4.9)	NC	Ref	Ref
Lagevrio					
Total	260,055	4,935 (1.9)	NC	NC	NC
Race					
AIAN/NHOPI	2,145	13 (0.6)	<0.001	-1.5	-70.9
Asian	12,062	101 (0.8)	<0.001	-1.2	-59.8
Black	30,482	561 (1.8)	0.005	-0.2	-11.7
White	187,369	3,907 (2.1)	NC	Ref	Ref
Multiple or other	12,396	117 (0.9)	<0.001	-1.1	-54.7
Ethnicity					
Hispanic	23,711	184 (0.8)	<0.001	-1.2	-61.7
non-Hispanic	217,739	4,407 (2.0)	NC	Ref	Ref
Veklury					
Total	260,055	1,648 (0.6)	NC	NC	NC
Race					
AIAN/NHOPI	2,145	5 (0.2)	0.030	-0.4	-61.5
Asian	12,062	45 (0.4)	0.001	-0.2	-38.3
Black	30,482	318 (1.0)	<0.001	0.4	72.5
White	187,369	1,133 (0.6)	NC	Ref	Ref
Multiple or other	12,396	81 (0.7)	0.500	0.0	8.1
Ethnicity					
Hispanic	23,711	108 (0.5)	<0.001	-0.2	-33.3
non-Hispanic	217,739	1,486 (0.7)	NC	Ref	Ref

Abbreviations: AIAN/NHOPI = American Indian or Alaska Native and Native Hawaiian or other Pacific Islander; NC = not calculated; Ref = referent group.

* COVID-19 patients were identified by a positive SARS-CoV-2 viral test result, an *International Classification of Diseases, Tenth Revision, Clinical Modification* diagnostic code for COVID-19 (U07.1 and U07.2), or treatment with a

COVID-19 medication (Paxlovid, Lagevrio, monoclonal antibodies, or Veklury). Patients were considered treated if they were prescribed Lagevrio or administered monoclonal antibodies or Veklury.

[†] Race and ethnicity were assessed as separate variables because the PCORnet distributed query statistical program does not allow for assessment of combined race and ethnicity by month or for shorter periods (April–July 2022).

Approximately 58% of multiple and other race patients were of Hispanic ethnicity.

[§] Number of patients with missing race and missing ethnicity are not shown. The number missing can be calculated by subtracting the number of patients with known race or ethnicity from the total number of patients.

[¶] Pearson's chi-square tests comparing percentage treated in the minority racial and ethnic groups with percentage treated in the majority or referent group (i.e., White race and non-Hispanic ethnicity).

** Absolute difference was calculated as the percentage treated in the minority racial and ethnic group minus the percentage treated in the majority or referent group (i.e., percentage point difference). Relative difference was calculated as the absolute difference divided by the percentage treated in the majority or referent group.

SUPPLEMENTARY TABLE 2. Absolute and relative differences in the percentage of COVID-19 patients aged ≥20 years treated with Paxlovid or monoclonal antibodies* by race and ethnicity,[†] and by immunocompromise[§] — PCORnet, the National Patient-Centered Clinical Research Network sites, 30 U.S. sites, January–July 2022

Immunocompromise group/ Race and ethnicity	No. of COVID-19 patients [¶]	Paxlovid treatment				mAb treatment			
		No. (%) treated [¶]	P-value**	Absolute difference in % treated ^{††}	Relative difference in % treated ^{††}	No. (%) treated [¶]	P-value**	Absolute difference in % treated ^{††}	Relative difference in % treated ^{††}
Previous Organ Transplant									
Total	9,457	406 (4.3)	NC	NC	NC	2,025 (21.4)	NC	NC	NC
Race									
AIAN/NHOPI	99	5 (5.1)	1.000	-0.1	-2.6	16 (16.2)	0.059	-8.8	-35.2
Asian	363	17 (4.7)	0.766	-0.5	-9.7	82 (22.6)	0.343	-2.4	-9.5
Black	2,123	36 (1.7)	<0.001	-3.5	-67.3	321 (15.1)	<0.001	-9.8	-39.4
White	5,863	304 (5.2)	NC	Ref	Ref	1,463 (25.0)	NC	Ref	Ref
Multiple or other	752	29 (3.9)	0.139	-1.3	-25.6	90 (12.0)	<0.001	-13.0	-52.0
Ethnicity									
Hispanic	1,057	37 (3.5)	0.200	-0.9	-20.5	141 (13.3)	<0.001	-9.1	-40.6
non-Hispanic	8,151	359 (4.4)	NC	Ref	Ref	1,831 (22.5)	NC	Ref	Ref
Active Cancer Treatment									
Total	17,967	2,917 (16.2)	NC	NC	NC	2,255 (12.6)	NC	NC	NC
Race									
AIAN/NHOPI	115	10 (8.7)	0.014	-9.3	-51.6	12 (10.4)	0.283	-4.0	-27.6
Asian	496	114 (23.0)	0.005	5.0	27.9	57 (11.5)	0.080	-2.9	-20.2
Black	2,443	207 (8.5)	<0.001	-9.5	-52.8	192 (7.9)	<0.001	-6.5	-45.4
White	13,254	2,381 (18.0)	NC	Ref	Ref	1,909 (14.4)	NC	Ref	Ref
Multiple or other	1,187	137 (11.5)	<0.001	-6.4	-35.8	48 (4.0)	<0.001	-10.4	-71.9
Ethnicity									
Hispanic	1,508	147 (9.7)	<0.001	-7.2	-42.4	74 (4.9)	<0.001	-8.4	-63.1
non-Hispanic	15,790	2,670 (16.9)	NC	Ref	Ref	2,099 (13.3)	NC	Ref	Ref
Corticosteroid Use									
Total	35,737	5,139 (14.4)	NC	NC	NC	3,078 (8.6)	NC	NC	NC
Race									
AIAN/NHOPI	290	35 (12.1)	0.084	-3.9	-24.4	18 (6.2)	0.098	-3.0	-32.5
Asian	794	127 (16.0)	1.000	0.0	0.1	83 (10.5)	0.255	1.3	13.6
Black	6,189	515 (8.3)	<0.001	-7.7	-47.9	418 (6.8)	<0.001	-2.4	-26.6
White	25,576	4,085 (16.0)	NC	Ref	Ref	2,353 (9.2)	NC	Ref	Ref
Multiple or other	1,870	223 (11.9)	<0.001	-4.0	-25.3	133 (7.1)	0.003	-2.1	-22.7
Ethnicity									
Hispanic	3,058	324 (10.6)	<0.001	-4.1	-27.7	185 (6.0)	<0.001	-2.8	-31.3
non-Hispanic	31,535	4,622 (14.7)	NC	Ref	Ref	2,775 (8.8)	NC	Ref	Ref
Immunosuppressive Medication Use									
Total	23,538	3,904 (16.6)	NC	NC	NC	3,572 (15.2)	NC	NC	NC
Race									

AIAN/NHOPI	190	20 (10.5)	0.006	-8.0	-39.7	16 (8.4)	0.003	-8.2	-49.4
Asian	775	156 (20.1)	0.279	1.6	19.6	117 (15.1)	0.279	-1.5	-9.3
Black	3,884	321 (8.3)	<0.001	-10.2	-55.4	462 (11.9)	<0.001	-4.7	-28.5
White	16,540	3,062 (18.5)	NC	Ref	Ref	2,753 (16.6)	NC	Ref	Ref
Multiple or other	1,484	204 (13.7)	<0.001	-4.8	-45.3	136 (9.2)	<0.001	-7.5	-44.9
Ethnicity									
Hispanic	2,154	244 (11.3)	<0.001	-5.6	-33.1	220 (10.2)	<0.001	-5.6	-35.5
non-Hispanic	20,573	3,484 (16.9)	NC	Ref	Ref	3,259 (15.8)	NC	Ref	Ref

Abbreviations: AIAN/NHOPI = American Indian or Alaska Native and Native Hawaiian or other Pacific Islander; ICD-10-CM = *International Classification of Diseases, Tenth Revision, Clinical Modification*; mAb = monoclonal antibody; NC = not calculated; Ref = referent group.

* COVID-19 patients were identified by a positive SARS-CoV-2 viral test result, an ICD-10-CM diagnostic code for COVID-19 (U07.1 and U07.2), or treatment with a COVID-19 medication (Paxlovid, Lagevrio, mAbs, or Veklury). Patients were considered treated if they were prescribed Paxlovid or administered mAbs. These two medications were selected because they were the most frequently used among patients with immunocompromise.

† Race and ethnicity were assessed as separate variables for patients with immunocompromise for consistency in presentation of results; the PCORnet distributed query statistical program does not allow for assessment of combined race and ethnicity by month or for shorter periods (April–July 2022). Approximately 58% of multiple and other race patients were of Hispanic ethnicity.

§ Patients with immunocompromise were identified as follows: prior organ transplant (≥ 1 ICD-10-CM code at any time preceding COVID-19); active cancer treatment (≥ 3 ICD-10-CM codes for cancer during the 6 months preceding COVID-19); corticosteroid use (≥ 2 prescriptions during the year preceding COVID-19); and immunosuppressive medication use (≥ 1 prescription for or administration of a noncorticosteroid immunosuppressive medication during the year preceding COVID-19).

¶ Number of patients with missing race and missing ethnicity are not shown. The number missing can be calculated by subtracting the number of patients with known race or ethnicity from the total number of patients.

**Pearson's chi-square tests comparing percentage treated in the minority racial and ethnic groups with percentage treated in the majority or referent group (i.e., White race and non-Hispanic ethnicity).

†† Absolute difference was calculated as the percentage treated in the minority racial and ethnic group minus the percentage treated in the majority or referent group (i.e., percentage point difference). Relative difference was calculated as the absolute difference divided by the percentage treated in the majority or referent group.